Form 4: Exelixis EVP Patrick Haley Executes Tax Withholding
Statement of Changes in Beneficial Ownership
EVP of Commercial Patrick J. Haley reported the withholding of 33,265 shares to satisfy tax obligations related to RSU vesting.
Summary
- Patrick J. Haley, EVP of Commercial at Exelixis, Inc., reported a transaction involving the withholding of 33,265 shares of common stock.
- The transaction occurred on May 15, 2026, at a price of $51.10 per share.
- The withholding was conducted to satisfy tax liabilities associated with the vesting of restricted stock units (RSUs) granted between 2022 and 2025.
- Following this transaction, the reporting person maintains a beneficial ownership of 389,748 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax compliance action by an executive rather than a change in strategic direction or market sentiment.
Positives
- The transaction is a routine administrative action related to tax obligations upon the vesting of equity awards, rather than a discretionary sale of shares.
Negatives
- None identified; this is a standard regulatory disclosure for executive compensation tax compliance.
Risks
- The reporting person's holdings remain subject to market volatility and the performance of Exelixis, Inc. common stock.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that tax-related share withholdings are standard industry practice for executives in the biotechnology sector to manage tax liabilities arising from equity compensation vesting schedules.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for executive compensation in the pharmaceutical and biotech industries.
- The use of Rule 10b5-1(c) plans or automatic tax withholding is a common mechanism used by executives at peers like Amgen or Gilead to ensure compliance with tax laws while avoiding potential insider trading concerns.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a standard tax-related equity settlement.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 03/04/2022 | Grant date of initial RSU award. |
| 04/03/2023 | Grant date of RSU award. |
| 02/23/2024 | Grant date of RSU award. |
| 02/26/2025 | Grant date of RSU award. |
| 03/31/2025 | Grant date of performance-based restricted stock unit award. |
| 04/30/2026 | Date of common stock acquisition via Employee Stock Purchase Plan. |
| 05/15/2026 | Date of the reported tax withholding transaction. |
| 05/19/2026 | Filing date of the Form 4. |
Keywords
Exelixis, EXEL, Form 4, Insider Trading, Executive Compensation, Tax Withholding, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.